News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

Jennifer Lo, PharmD

Advertisement

Articles by Jennifer Lo, PharmD

"Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

ByBradley Langford, PharmD, BCPS*,Jennifer Lo, PharmD,Kevin Schwartz, MD, MSc, FRCPC
October 15th 2019

By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population.

Advertisement

Latest Updated Articles

  • "Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure
    "Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

    Published: October 15th 2019 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

Developing a COVID-19 Vaccine Alternative

2

Generic Lenacapavir Could Cost as Little as $25 Per Person Annually

3

Real-World Data Reinforce Effectiveness and Safety of Fecal Microbiota Therapy for Preventing Recurrent C difficile

4

Early, Aggressive Treatment and Shorter Antibiotic Courses Shape Modern Pneumonia Discharge Practices

5

Practically Expanding AI's role in Infectious Diseases

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us